iTolerance

I Tolerance

Biotechnology, Miami, Florida, 33136, United States, 1-10 Employees

itolerance.com

  • facebook
  • twitter
  • LinkedIn

Who is ITOLERANCE

iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technol...

Read More

map
  • Miami, Florida, 33136, United States Headquarters: Miami, Florida, 33136, United States
  • 2020 Date Founded: 2020
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

checked-icon Does something look wrong? Fix it. | View contact records from ITOLERANCE

iTolerance Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding ITolerance

Answer: iTolerance's headquarters are located at Miami, Florida, 33136, United States

Answer: iTolerance's official website is https://itolerance.com

Answer: iTolerance's revenue is Under $1 Million

Answer: iTolerance has 1-10 employees

Answer: iTolerance is in Biotechnology

Answer: iTolerance contact info: Phone number: Website: https://itolerance.com

Answer: iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, iTOL-100, we are advancing a pipeline of programs using both allogenic pancreatic islets and stem-cells that have the potential to cure diseases. Our lead program, iTOL-101 is being developed for Type 1 Diabetes and in a preclinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows a potentially inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access